GlycoMimetics EBIT Margin 2012-2024 | GLYC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

GlycoMimetics ebit margin from 2012 to 2024. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

GlycoMimetics ebit margin from 2012 to 2024. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$73.4B
Chugai Pharmaceutical (CHGCY)	$72.5B
Takeda Pharmaceutical (TAK)	$42.2B
Merck (MKKGY)	$18.5B
Sandoz Group AG (SDZNY)	$17.9B
Astellas Pharma (ALPMY)	$17.4B
United Therapeutics (UTHR)	$16.1B
Neurocrine Biosciences (NBIX)	$14B
Summit Therapeutics (SMMT)	$13.5B
Shionogi (SGIOY)	$11.9B
Madrigal Pharmaceuticals (MDGL)	$6.8B
Orion OYJ (ORINY)	$6.2B
Ionis Pharmaceuticals (IONS)	$5.5B
Corcept Therapeutics (CORT)	$5.2B
Crinetics Pharmaceuticals (CRNX)	$4.8B
PTC Therapeutics (PTCT)	$3.5B
Recursion Pharmaceuticals (RXRX)	$2.8B
Dyne Therapeutics (DYN)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.4B
NewAmsterdam Pharma (NAMS)	$2.4B
Centessa Pharmaceuticals (CNTA)	$2.3B
Soleno Therapeutics (SLNO)	$2B
Indivior (INDV)	$1.7B
Xencor (XNCR)	$1.7B
BioCryst Pharmaceuticals (BCRX)	$1.6B
Evotec AG (EVO)	$1.5B
Ocular Therapeutix (OCUL)	$1.4B
Harrow (HROW)	$1.3B
Guardian Pharmacy Services (GRDN)	$1.3B